Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
411 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00261846 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | completed | Phase 2 | 571 | PfizerINDUSTRY | 27 | Jul 27, 2017 | clinicaltrials |
| NCT02016534 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | terminated | Phase 2 | 60 | AmgenINDUSTRY | 18 | Jul 2, 2017 | clinicaltrials |
| NCT01205217 |
| Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer(ELATE) |
| withdrawn |
| Phase 2 |
| 0 |
| GlaxoSmithKlineINDUSTRY |
| 4 |
| Jun 7, 2017 |
| clinicaltrials |
| NCT01440374 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia(ASPIRE) | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 5, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT01641939 | A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer | terminated | Phase 2 / Phase 3 | 415 | Hoffmann-La RocheINDUSTRY | 28 | May 12, 2017 | clinicaltrials |
| NCT01493843 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | completed | Phase 2 | 501 | Genentech, Inc.INDUSTRY | 16 | Apr 25, 2017 | clinicaltrials |
| NCT02212197 | Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer | completed | Phase 2 | 51 | Camurus ABINDUSTRY | 2 | Apr 25, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT00102726 | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy | completed | Phase 2 | 183 | GlaxoSmithKlineINDUSTRY | 19 | Mar 23, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT01457846 | Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer(SHINE) | terminated | Phase 2 | 960 | AstraZenecaINDUSTRY | 16 | Mar 7, 2017 | clinicaltrials |
| NCT01667536 | A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | completed | Phase 2 | 105 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 8 | Feb 7, 2017 | clinicaltrials |
| NCT01040832 | EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 107 | EMD SeronoINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT02150213 | Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 5, 2016 | clinicaltrials |
| NCT02465814 | Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids(ASTEROID 2) | completed | Phase 2 | 120 | BayerINDUSTRY | 16 | Nov 22, 2016 | clinicaltrials |
| NCT01577173 | A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck | completed | Phase 2 | 122 | Genentech, Inc.INDUSTRY | 11 | Nov 2, 2016 | clinicaltrials |
| NCT01715896 | A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis | completed | Phase 2 | 215 | MedImmune LLCINDUSTRY | 14 | Oct 31, 2016 | clinicaltrials |
| NCT00813605 | QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma | completed | Phase 2 | 155 | NantCell, Inc.INDUSTRY | 10 | Oct 27, 2016 | clinicaltrials |
| NCT00498797 | E3-Hormone Refractory Prostrate Cancer Taxotere Combination | completed | Phase 2 | 86 | SanofiINDUSTRY | 5 | Oct 7, 2016 | clinicaltrials |
| NCT00494481 | E3 Breast Cancer Taxotere Combination | completed | Phase 2 | 64 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Sep 30, 2016 | clinicaltrials |
| NCT01826214 | Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 30, 2016 | clinicaltrials |
| NCT00047840 | This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | completed | Phase 2 | 129 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Aug 25, 2016 | clinicaltrials |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 37 | Hoffmann-La RocheINDUSTRY | 10 | Aug 24, 2016 | clinicaltrials |
| NCT00327535 | A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 15 | Aug 11, 2016 | clinicaltrials |
| NCT00682981 | A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) | completed | Phase 1 / Phase 2 | 218 | Gemin XINDUSTRY | 10 | Jul 21, 2016 | clinicaltrials |
| NCT01528345 | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | terminated | Phase 2 | 97 | Novartis PharmaceuticalsINDUSTRY | 15 | Jul 11, 2016 | clinicaltrials |
| NCT00444587 | A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 2 | 114 | Hoffmann-La RocheINDUSTRY | 8 | Jun 21, 2016 | clinicaltrials |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | completed | Phase 2 | 130 | GlaxoSmithKlineINDUSTRY | 13 | Apr 18, 2016 | clinicaltrials |
| NCT01390545 | VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis(VELVET) | terminated | Phase 2 | 300 | TakedaINDUSTRY | 11 | Apr 13, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT00347919 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 2 | 189 | GlaxoSmithKlineINDUSTRY | 16 | Feb 25, 2016 | clinicaltrials |
| NCT00479752 | Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer(CORE 2) | completed | Phase 2 | 151 | Central European Cooperative Oncology GroupOTHER | 13 | Feb 18, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT00297258 | Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | completed | Phase 2 | 148 | GlaxoSmithKlineINDUSTRY | 5 | Feb 3, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT01056341 | Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy | completed | Phase 2 / Phase 3 | 512 | Pierre Fabre DermatologyINDUSTRY | 16 | Dec 10, 2015 | clinicaltrials |
| NCT00511459 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | completed | Phase 2 | 228 | AmgenINDUSTRY | 13 | Oct 29, 2015 | clinicaltrials |
| NCT01161368 | A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients | terminated | Phase 2 | 9 | Central European Cooperative Oncology GroupOTHER | 2 | Aug 13, 2015 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials